公开(公告)号：US20230390317A1

公开(公告)日：2023-12-07

申请号：US18170704

申请日：2023-02-17

申请人： CELATOR PHARMACEUTICALS, INC.

发明人： Mark E. HAYES ,  Charles O. NOBEL ,  Francis C. SZOKA

IPC分类号： A61K31/7048 ,  A61K9/127 ,  A61K31/395 ,  A61K31/704 ,  A61K9/19 ,  A61K31/337 ,  A61K31/4196 ,  A61K31/496 ,  A61K38/07 ,  A61K47/02

CPC分类号： A61K31/7048 ,  A61K9/127 ,  A61K9/1271 ,  A61K31/395 ,  A61K31/704 ,  A61K9/1277 ,  A61K9/19 ,  A61K31/337 ,  A61K31/4196 ,  A61K31/496 ,  A61K38/07 ,  A61K47/02

摘要： The present invention provides liposome compositions containing sparingly soluble drugs that are used to treat life-threatening diseases. A preferred method of encapsulating a drug inside a liposome is by remote or active loading. Remote loading of a drug into liposomes containing a transmembrane electrochemical gradient is initiated by co-mixing a liposome suspension with a solution of drug, whereby the neutral form of the compound freely enters the liposome and becomes electrostatically charged thereby preventing the reverse transfer out of the liposome. There is a continuous build-up of compound within the liposome interior until the electrochemical gradient is dissipated or all the drug is encapsulated in the liposome. However, this process as described in the literature has been limited to drugs that are freely soluble in aqueous solution or solubilized as a water-soluble complex. This invention describes compositions and methods for remote loading drugs with low water solubility (

公开(公告)号：US10927418B2

公开(公告)日：2021-02-23

申请号：US15774978

申请日：2016-11-10

申请人： CELATOR PHARMACEUTICALS, INC. ,  OREGON HEALTH & SCIENCE UNIVERSITY

发明人： Max Gordon ,  Paul Tardi ,  Jeffrey Tyner ,  Lawrence Mayer

IPC分类号： A61K31/5377 ,  A61K31/704 ,  A61K31/7068 ,  A61K31/4709 ,  A61K31/517 ,  A61K31/496 ,  A61K31/44 ,  A61K31/506 ,  A61K31/553 ,  A61P35/02 ,  A61K31/407 ,  C12Q1/6886 ,  C12Q1/68 ,  A61K9/127

摘要： Diagnostic methods for identifying cancer bearing subjects appropriate for treatment with CPX-351 include genetic and ex vivo testing of cells from a candidate subject. Combination treatment with CPX-351 and FLT-3 inhibitors improve CPX-351 uptake and toxicity.

公开(公告)号：US10722464B2

公开(公告)日：2020-07-28

申请号：US16048100

申请日：2018-07-27

申请人： Celator Pharmaceuticals, Inc. ,  Lawrence Mayer

发明人： Paul Tardi ,  Troy Harasym ,  Murray Webb ,  Clifford Shew ,  Andrew Janoff ,  Lawrence Mayer ,  Marcel Bally

IPC分类号： A61K9/127 ,  A61K31/00 ,  A61K31/337 ,  A61K31/4745 ,  A61K31/704 ,  A61K31/7048 ,  A61K31/7072 ,  A61K31/7076 ,  A61K33/24 ,  A61K45/06 ,  A61K31/133 ,  A61K31/17 ,  A61K31/475 ,  A61K31/513 ,  A61K31/519 ,  A61K31/555 ,  A61K31/575 ,  A61K31/685 ,  A61K31/7068 ,  A61K39/00

摘要： Compositions which comprise delivery vehicles having stably associated therewith non-antagonistic combinations of two or more agents, such as antineoplastic agents, are useful in achieving non-antagonistic effects when combinations of drugs are administered.

公开(公告)号：US20180207104A1

公开(公告)日：2018-07-26

申请号：US15744723

申请日：2016-07-14

申请人： CELATOR PHARMACEUTICALS, INC.

发明人： Leon WAN ,  Winnie LUI ,  Paul TARDI ,  Lawrence MAYER

IPC分类号： A61K9/51 ,  A61K47/54 ,  A61K31/5377 ,  A61K31/337 ,  A61K31/4184 ,  A61K31/517

CPC分类号： A61K9/5153 ,  A61K9/0019 ,  A61K9/5192 ,  A61K31/337 ,  A61K31/4184 ,  A61K31/517 ,  A61K31/5377 ,  A61K47/554

摘要： Nanopaiticle compositions described herein comprise combinations of prodrugs of therapeutic agents that achieve enhanced therapeutic effects as compared to those observed when combinations of free forms of these therapeutic agents are administered.

公开(公告)号：US20180161273A1

公开(公告)日：2018-06-14

申请号：US15891170

申请日：2018-02-07

申请人： CELATOR PHARMACEUTICALS INC.

发明人： Donna CABRAL-LILLY ,  Lawrence MAYER ,  Paul TARDI ,  David WATKINS ,  Yi ZENG

IPC分类号： A61K9/127 ,  A61K31/7072 ,  A61K31/7068 ,  A61K31/704 ,  A61K31/4745 ,  A61K9/19 ,  A61K47/26 ,  A61K45/06

CPC分类号： A61K9/127 ,  A61K9/1277 ,  A61K9/19 ,  A61K31/4745 ,  A61K31/704 ,  A61K31/7068 ,  A61K31/7072 ,  A61K45/06 ,  A61K47/26

摘要： Lyophilized liposomal formulations with two or more encapsulated drugs are disclosed. These formulations display superior drug retention profiles and also maintain size distribution following lyophilization and reconstitution.

公开(公告)号：US20120009252A1

公开(公告)日：2012-01-12

申请号：US13237807

申请日：2011-09-20

申请人： Lawrence MAYER ,  Sharon Johnstone ,  Troy Harasym

发明人： Lawrence MAYER ,  Sharon Johnstone ,  Troy Harasym

IPC分类号： A61K9/127 ,  A61P35/00 ,  A61K31/704 ,  B82Y5/00

CPC分类号： A61K9/127 ,  A61K9/1278 ,  A61K31/704 ,  A61K31/706 ,  A61K31/7068 ,  Y10S977/801 ,  A61K2300/00

摘要： Compositions which comprise an anthracycline agent, and a cytidine analog are encapsulated in liposomal carriers. The preferred anthracycline agent is selected from the group of daunorubicin, doxorubicin, and idarubicin, while the preferred cytidine analog is selected from the group of cytarabine, gemcitabine, or 5-azacytidine. The combination of the anthracycline agent and cytidine analog encapsulated in said liposomal carriers are useful in achieving a drug retention and a sustained drug release for each therapeutic agent.

摘要翻译： 包含蒽环类药物和胞苷类似物的组合物被包封在脂质体载体中。 优选的蒽环类药物选自柔红霉素，多柔比星和伊达比星组，而优选的胞苷类似物选自阿糖胞苷，吉西他滨或5-氮杂胞苷组。 包封在所述脂质体载体中的蒽环类药物和胞苷类似物的组合可用于实现每种治疗剂的药物保留和持续的药物释放。

公开(公告)号：US08092828B2

公开(公告)日：2012-01-10

申请号：US12032583

申请日：2008-02-15

申请人： Arthur Louie ,  Christine Swenson ,  Lawrence Mayer ,  Andrew Janoff

发明人： Arthur Louie ,  Christine Swenson ,  Lawrence Mayer ,  Andrew Janoff

IPC分类号： A61K9/127 ,  A61K31/00

CPC分类号： A61K31/70 ,  A61K9/0019 ,  A61K9/127 ,  Y10T436/143333

摘要： Provided herein are methods for treating cancer by administering a pharmaceutical composition comprising a fixed, non-antagonistic molar ratio of cytarabine and an anthracycline. Such methods are particularly useful in the treatment of patients with advanced hematologic cancers or proliferative disorders.

摘要翻译： 本文提供了通过施用包含固定的，非拮抗摩尔比的阿糖胞苷和蒽环类药物的药物组合物来治疗癌症的方法。 这种方法在治疗晚期血液癌或增殖性疾病的患者中特别有用。

公开(公告)号：US11413253B2

公开(公告)日：2022-08-16

申请号：US17013101

申请日：2020-09-04

申请人： Celator Pharmaceuticals, Inc.

发明人： Leon Wan ,  Winnie Lui ,  Paul Tardi ,  Lawrence Mayer

IPC分类号： A61K9/51 ,  A61K9/00 ,  A61K47/54 ,  A61K31/337 ,  A61K31/4184 ,  A61K31/517 ,  A61K31/5377

摘要： Nanoparticle compositions described herein comprise combinations of prodrugs of therapeutic agents that achieve enhanced therapeutic effects as compared to those observed when combinations of free forms of these therapeutic agents are administered.

公开(公告)号：US20210393665A1

公开(公告)日：2021-12-23

申请号：US17338561

申请日：2021-06-03

申请人： Celator Pharmaceuticals, Inc.

发明人： Ronald CHEUNG ,  Stefan FADERL ,  Qi WANG

IPC分类号： A61K31/7068 ,  A61K31/704 ,  A61K9/00 ,  A61K31/635 ,  A61P35/02 ,  A61K31/553 ,  A61K39/395 ,  A61K31/53

摘要： The invention relates to compositions and methods for treating patients with hematological proliferative disorders who are ineligible for treatment with standard intensive chemotherapy, using low intensity treatment with CPX-351, a liposomal composition of daunorubicin and cytarabine.

公开(公告)号：US11028076B2

公开(公告)日：2021-06-08

申请号：US16745709

申请日：2020-01-17

申请人： Celator Pharmaceuticals, Inc.

发明人： Daryl C. Drummond ,  Bolin Geng ,  Dmitri B. Kirpotin ,  Suresh K. Tipparaju ,  Alexander Koshkaryev ,  Ozan Alkan

IPC分类号： C07D403/12 ,  A61K9/127 ,  A61K31/496 ,  A61K31/555 ,  A61K31/4745 ,  A61K31/7068 ,  A61K31/497 ,  A61K31/4965 ,  A61P35/00 ,  A61K47/14

摘要： Novel compounds inhibiting ATR protein kinase include compounds of formula (I) disclosed herein, as well as liposome formulations comprising ATR protein kinase inhibitor compounds. The compositions are useful for the treatment of cancer.